The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Understanding the plasticity of elusive tumor cells to improve treatment for patients with myeloma
Francesco Maura, MD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, comments on the lack of knowledge surrounding how to engage elusive tumor cells with immune effectors in multiple myeloma (MM), stating that the plasticity of tumor cells under the selective pressure of therapy is not yet fully understood. Dr Maura emphasizes the need to identify how tumor cells change their profile and proteomic surface to evade therapy in order to develop new treatment strategies for patients. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
Well, that’s a great question, and it’s kind of like right now we don’t know the answer. And the reason why we don’t know is because we don’t know how the plasticity of the cells change their profile and the proteomic surface under the selective pressure of the therapy. So we know how a tumor cell looks like before the therapy. But we don’t know after two weeks of CAR-T or bispecifics how that changes...
Well, that’s a great question, and it’s kind of like right now we don’t know the answer. And the reason why we don’t know is because we don’t know how the plasticity of the cells change their profile and the proteomic surface under the selective pressure of the therapy. So we know how a tumor cell looks like before the therapy. But we don’t know after two weeks of CAR-T or bispecifics how that changes. And we know it’s changing. There are studies showing that. So I guess the key for the future is to try to understand how this plasticity affects this tumor evolution. And if we know that there is, for example, a new target, let’s say a protein that is not expressed in myeloma, that after 10 days of this CAR-T is actually expressed, allowing the tumor to hide, then you have a new marker and you can get, for example, another CAR-T. So I think identifying this plasticity and how the cell transitions from one state to another will also allow us to identify new targets and eventually eradicate these dormant or frozen cells.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
